X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
As part of the agreement, FFTC will receive direct access to PRESECO data in support of local regulatory submissions in Japan. PRESECO is investigating the safety and efficacy of Avigan/Reeqonus in the early treatment outpatient setting for adults infected with COVID-19.
Lead Product(s): Favipiravir
Therapeutic Area: Infections and Infectious Diseases Product Name: Avigan
Highest Development Status: Phase IIIProduct Type: Small molecule
Recipient: Appili Therapeutics
Deal Size: $1.0 million Upfront Cash: Undisclosed
Deal Type: Agreement September 20, 2021
Details:
FUJIFILM Cellular Dynamics grants Sana a non-exclusive license under intellectual property rights owned or controlled by FUJIFILM Cellular Dynamics, and will provide iPSC cell lines (including research-grade and/or Good Manufacturing Practices (GMP)-grade iPSC lines) to Sana.
Lead Product(s): iPSC-Derived Cell Therapies
Therapeutic Area: Immunology Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Sana Biotechnology
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement March 16, 2021
Details:
Japan has approved Avigan, known generically as favipiravir, as an emergency flu medicine. But concerns remain, as the drug has been shown to cause birth defects in animal studies and its effectiveness against COVID-19 has proven difficult to demonstrate.
Lead Product(s): Favipiravir
Therapeutic Area: Infections and Infectious Diseases Product Name: Avigan
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 21, 2021
Details:
The meta-analysis of nine clinical trials showed the drug, known generically as favipiravir, helped patients early on in their hospitalisation but failed to demonstrate statistically significant results in reducing mortality among those with mild to moderate COVID-19.
Lead Product(s): Favipiravir
Therapeutic Area: Infections and Infectious Diseases Product Name: Avigan
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 18, 2021
Details:
The Japanese Health Ministry said on Monday its medical review board concluded that clinical trial data to determine the efficacy of Fujifilm Holdings Corp’s COVID-19 drug candidate Avigan is inconclusive.
Lead Product(s): Favipiravir
Therapeutic Area: Infections and Infectious Diseases Product Name: Avigan
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 21, 2020
Details:
FUJIFILM Toyama Chemical has partnered with Carelink towards the deployment of Avigan in China, and signed a memorandum to grant Carelink the exclusive right to submit an application for imported drug approval.
Lead Product(s): Favipiravir
Therapeutic Area: Infections and Infectious Diseases Product Name: Avigan
Highest Development Status: Phase IIIProduct Type: Small molecule
Recipient: Carelink
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership October 22, 2020
Details:
FUJIFILM conducted a phase III trial in Japan for COVID-19 patients with non-severe pneumonia. Based on the results, it seeks to add, indication as well as dosage and administration concerning COVID-19 to the current manufacturing and marketing approval items of Avigan.
Lead Product(s): Favipiravir
Therapeutic Area: Infections and Infectious Diseases Product Name: Avigan
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 16, 2020
Details:
Fujifilm will utilize its manufacturing facilities and infrastructure for lipid nanoparticle to handle operations relating to VLP Therapeutics' COVID-19 vaccine formulations, from process development to manufacturing for clinical trials.
Lead Product(s): COVID 19 vaccine
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: UndisclosedProduct Type: Vaccine
Partner/Sponsor/Collaborator: VLP Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement October 01, 2020
Details:
The efficacy primary endpoint is time to negative conversion of detectable SARS-CoV 2 viral RNA in the RT-PCR assays, and to alleviation of symptoms (body temperature, oxygen saturation and chest images).
Lead Product(s): Favipiravir
Therapeutic Area: Infections and Infectious Diseases Product Name: Avigan
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 23, 2020
Details:
Although patients given the drug early in the trial showed more improvement than those who got delayed doses, the results did not reach statistical significance.
Lead Product(s): Favipiravir
Therapeutic Area: Infections and Infectious Diseases Product Name: Avigan
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 10, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
